BG103169A - Лиганд сроден с тумор некрозис фактор - Google Patents

Лиганд сроден с тумор некрозис фактор

Info

Publication number
BG103169A
BG103169A BG103169A BG10316999A BG103169A BG 103169 A BG103169 A BG 103169A BG 103169 A BG103169 A BG 103169A BG 10316999 A BG10316999 A BG 10316999A BG 103169 A BG103169 A BG 103169A
Authority
BG
Bulgaria
Prior art keywords
necrotic factor
ligand related
tumour
tumour necrotic
ligand
Prior art date
Application number
BG103169A
Other languages
English (en)
Other versions
BG64779B1 (bg
Inventor
Yves Chicheportiche
Jeffrey Browning
Original Assignee
Biogen Idec Ma Inc.
The Faculty Of Medicine Of The University Of Geneva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc., The Faculty Of Medicine Of The University Of Geneva filed Critical Biogen Idec Ma Inc.
Publication of BG103169A publication Critical patent/BG103169A/bg
Publication of BG64779B1 publication Critical patent/BG64779B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

Изобретението се отнася до лиганд, свързан с тумор некрозисен фактор (TRELL), един нов тумор некрозисен фактор фамилията (TNF), модифициран TRELL и до фармацевтични препарати, които ги включват.
BG103169A 1996-08-07 1999-02-11 Лиганд сроден с тумор некрозис фактор BG64779B1 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2354196P 1996-08-07 1996-08-07
US2851596P 1996-10-18 1996-10-18
US4082097P 1997-03-18 1997-03-18

Publications (2)

Publication Number Publication Date
BG103169A true BG103169A (bg) 2000-06-30
BG64779B1 BG64779B1 (bg) 2006-03-31

Family

ID=27362110

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103169A BG64779B1 (bg) 1996-08-07 1999-02-11 Лиганд сроден с тумор некрозис фактор

Country Status (26)

Country Link
EP (2) EP0956351B1 (bg)
JP (3) JP4161084B2 (bg)
KR (1) KR100543730B1 (bg)
CN (2) CN101024831A (bg)
AT (1) ATE307204T1 (bg)
AU (1) AU736289B2 (bg)
BG (1) BG64779B1 (bg)
BR (1) BR9711046A (bg)
CA (1) CA2262756C (bg)
CZ (1) CZ297387B6 (bg)
DE (1) DE69734397T2 (bg)
DK (1) DK0956351T3 (bg)
EA (1) EA003187B1 (bg)
EE (1) EE05276B1 (bg)
ES (1) ES2251737T3 (bg)
HK (1) HK1025994A1 (bg)
HU (1) HU226787B1 (bg)
IL (1) IL128407A (bg)
IS (1) IS2606B (bg)
NO (2) NO326967B1 (bg)
NZ (1) NZ334107A (bg)
PL (1) PL188102B1 (bg)
SI (1) SI0956351T1 (bg)
SK (1) SK288012B6 (bg)
TR (1) TR199900903T2 (bg)
WO (1) WO1998005783A1 (bg)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011791A2 (en) * 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
AU749948B2 (en) * 1997-10-10 2002-07-04 Genentech Inc. APO-3 ligand
DE19829550C1 (de) * 1998-07-02 2000-01-27 Bosch Gmbh Robert Vorrichtung zum Verbinden von Bauteilen
TR200102021T2 (tr) * 1999-01-15 2001-12-21 Biogen, Inc. TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
US6994976B1 (en) 1999-11-19 2006-02-07 Tittle Thomas V Tr3-specific binding agents and methods for their use
WO2001035995A2 (en) * 1999-11-19 2001-05-25 Tittle Thomas V Tr3-specific binding agents and methods for their use
WO2001045730A2 (en) * 1999-12-20 2001-06-28 Immunex Corporation Tweak receptor
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
US7495086B2 (en) 1999-12-20 2009-02-24 Immunex Corporation TWEAK receptor
JP2004500844A (ja) 2000-05-08 2004-01-15 バイオジェン　インコーポレイテッド Ｔｗｅａｋアゴニストおよび血管形成因子を使用する、新血管新生を促進するための方法
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
ES2444121T3 (es) 2002-04-09 2014-02-24 Biogen Idec Ma Inc. Procedimientos para tratar afecciones relacionadas con TWEAK
EP2311867A1 (en) * 2002-10-29 2011-04-20 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines
WO2006089095A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
AU2006244014B2 (en) 2005-05-10 2011-03-17 Biogen Ma Inc. Treating and evaluating inflammatory disorders
CN101247830B (zh) 2005-05-27 2013-03-27 比奥根艾迪克Ma公司 结合tweak的抗体
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
CN103154029B (zh) 2010-10-05 2015-11-25 弗·哈夫曼-拉罗切有限公司 抗人tweak的抗体及其用途
EP2834273B1 (en) 2012-04-05 2018-08-22 F.Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
WO2018079864A1 (ko) * 2016-10-24 2018-05-03 김성천 TNF-α 결합 압타머 및 그것의 치료적 용도
JP7397446B2 (ja) * 2018-04-20 2023-12-13 中央研究院 Ｔｎｆ関連炎症性疾患を治療または診断するｔｎｆ指向性アプタマーおよびその使用
WO2022217283A1 (en) 2021-04-08 2022-10-13 Joslin Diabetes Center, Inc. Methods of diagnosing and predicting renal decline

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
IE902820A1 (en) 1989-08-07 1991-02-27 Merck & Co Inc Peptide inhibitors of human papilloma virus protein binding¹to retinoblastoma gene proteins
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
CA2077322A1 (en) 1991-09-04 1993-03-05 Allen I. Oliff Peptide inhibitors of human papilloma virus protein binding to retinoblastoma gene proteins

Also Published As

Publication number Publication date
EP0956351B1 (en) 2005-10-19
EP1591530A2 (en) 2005-11-02
NO20084906L (no) 1999-04-06
CZ40399A3 (cs) 1999-08-11
CA2262756A1 (en) 1998-02-12
ES2251737T3 (es) 2006-05-01
HU226787B1 (en) 2009-10-28
KR20000029877A (ko) 2000-05-25
CN101024831A (zh) 2007-08-29
CN1308451C (zh) 2007-04-04
EA003187B1 (ru) 2003-02-27
DE69734397T2 (de) 2006-07-06
SK288012B6 (sk) 2012-10-02
PL331583A1 (en) 1999-07-19
HK1025994A1 (en) 2000-12-01
EA199900187A1 (ru) 1999-08-26
CZ297387B6 (cs) 2006-11-15
AU3829497A (en) 1998-02-25
TR199900903T2 (xx) 1999-06-21
EP0956351A1 (en) 1999-11-17
HUP9903921A2 (hu) 2000-03-28
PL188102B1 (pl) 2004-12-31
BG64779B1 (bg) 2006-03-31
WO1998005783A1 (en) 1998-02-12
BR9711046A (pt) 2000-01-11
NZ334107A (en) 2000-06-23
JP2007204480A (ja) 2007-08-16
EE9900043A (et) 1999-08-16
DK0956351T3 (da) 2006-02-20
NO326967B1 (no) 2009-03-23
EP1591530A3 (en) 2009-04-08
IS4967A (is) 1999-02-05
NO990550D0 (no) 1999-02-05
HUP9903921A3 (en) 2000-08-28
NO990550L (no) 1999-04-06
JP2001505407A (ja) 2001-04-24
SI0956351T1 (sl) 2006-02-28
CN1232503A (zh) 1999-10-20
JP4161084B2 (ja) 2008-10-08
DE69734397D1 (de) 2006-03-02
ATE307204T1 (de) 2005-11-15
JP4411330B2 (ja) 2010-02-10
CA2262756C (en) 2012-06-12
JP2009183294A (ja) 2009-08-20
EP1591530B1 (en) 2015-02-25
IL128407A0 (en) 2000-01-31
EP1591530B8 (en) 2015-04-22
IS2606B (is) 2010-04-15
EE05276B1 (et) 2010-02-15
AU736289B2 (en) 2001-07-26
IL128407A (en) 2007-07-24
SK15799A3 (en) 2000-03-13
KR100543730B1 (ko) 2006-01-23

Similar Documents

Publication Publication Date Title
BG103169A (bg) Лиганд сроден с тумор некрозис фактор
ZA971324B (en) Powdered medication inhaler.
NO20001240L (no) Kay-A immunsystemprotein
PH31059A (en) Pharmaceutical compositions comprising cyclosporins.
EP0655256A3 (en) Inhaler.
EP0670716A4 (en) TASTE-MASKED PHARMACEUTICAL SUBSTANCES.
ZA975533B (en) Cyclosporin-containing pharmaceutical composition.
GR3031711T3 (en) Cephalosporins and homologues, preparations and pharmaceutical compositions.
GB2224316B (en) Two-cylinder-type rotary compressor.
ZA200104280B (en) Pharmaceutical combination preparations.
GB2220708B (en) Scroll compressors.
GB2223274B (en) Pumps.
ZA978383B (en) Pharmaceutical compositions comprising amisulpride and therapeutic applications thereof.
AU7624598A (en) 1,4-diazabicyclo (2.2.2) Oct-2-ylmethyl derivatives, their preparation and the rapeutic application
HK1001404A1 (en) Isolated, tyrosinase derived peptides and uses thereof.
BG102667A (bg) Състав, съдържащ диосгенин
IL114712A0 (en) Microparticle preparations for eliminating dissolved substances from the blood
ZA972708B (en) Pharmaceutical compositions and methods for the manufacture thereof.
ZA93694B (en) Pharmaceutical treatments.
ZA936739B (en) Antislip preparations.
GB2325409B (en) Pharmaceutical use of ondansetron/cyclodextrin complexes
FR2700540B1 (fr) alpha-méthyl-(R)-tryptophyl-arylcycloalkylalkylamides ligands aux récepteurs des gastrines, leur préparation et leur utilisation en thérapeutique.
ZA9610510B (en) Novel peptides, the preparation and use thereof.
EP0662782A4 (en) THERAPY BASED ON PP14.
ZA974422B (en) Substituted-amidinobenzene derivative and pharmaceutical compositions thereof.